Press release
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Melanoma research. Learn more about our innovative pipeline today! @ Melanoma Pipeline Outlook [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Melanoma Pipeline Report
* In February 2025, Iovance Biotherapeutics Inc . initiated a Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of lifileucel in combination with pembrolizumab versus pembrolizumab alone in patients with untreated, unresectable, or metastatic melanoma. Participants in the pembrolizumab monotherapy arm who experience confirmed progressive disease (PD), as verified by a blinded independent central review, will have the option to receive lifileucel monotherapy in a crossover period.
* In February 2025, Regeneron Pharmaceuticals launched a study investigating the experimental drug fianlimab (REGN3767) in combination with cemiplimab (REGN2810) for the treatment of melanoma. The study aims to assess the safety and efficacy of this combination compared to relatlimab and nivolumab (Opdualag Trademark ), an FDA-approved treatment for melanoma in adults and children.
* DelveInsight's Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
* The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics , and others.
* Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF , and others.
Stay informed about the cutting-edge advancements in Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Melanoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Melanoma Emerging Drugs Profile
* IO102 IO103 : IO Biotech
IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win Registered vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.
* mRNA 4157: Moderna Inc.
mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. The drug is been developed jointly by Moderna & Merck. Currently being evaluated in the Phase III studies.
* MK-4830: Merck Sharp & Dohme LLC
MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Colorectal Cancer.
* BNT111: BioNTech SE
BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.
* TILT 123: TILT Biotherapeutics LLC
TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.
The Melanoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Melanoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma Treatment.
* Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Melanoma market.
Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ Melanoma Unmet Needs [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Melanoma Companies
IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical
Melanoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Melanoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Melanoma Pipeline Report
* Coverage- Global
* Melanoma Companies- IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
* Melanoma Therapies- Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
* Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Melanoma Pipeline on our website @ Melanoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Melanoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* IO102 IO103 : IO Biotech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MK-4830: Merck Sharp & Dohme LLC
* Early Stage Products (Phase I)
* Comparative Analysis
* TILT 123: TILT Biotherapeutics LLC
* Inactive Products
* Melanoma Key Companies
* Melanoma Key Products
* Melanoma- Unmet Needs
* Melanoma- Market Drivers and Barriers
* Melanoma- Future Perspectives and Conclusion
* Melanoma Analyst Views
* Melanoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=melanoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3899951 • Views: …
More Releases from ABNewswire
Hyperphosphatemia Market Size was ~ USD 4 billion in 2023, estimates DelveInsigh …
Hyperphosphatemia companies are Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo and others.
The hyperphosphatemia market in the 7MM is projected to grow, driven by rising chronic kidney disease (CKD) prevalence and an expanding patient pool. US…
Mugslurp Coffee Unwraps a Cozy Holiday Season With Small-Batch Roasts, Nature-In …
Mugslurp Coffee rings in the holiday season with premium small-batch coffees, nature-inspired teas, and festive sample packs perfect for gifting. Known for hand-selected beans, fresh roasting, and the nostalgic charm of small-town simplicity, Mugslurp invites shoppers to savor slow moments and share warm cups all season long.
The holiday season gets a lot cozier this year as Mugslurp Coffee, the small-batch coffee brand inspired by nature's calm and the comfort of…
Positive Black Images Celebrates 35+ Years of Cultural Preservation Through Art
With over three decades of operation, Positive Black Images has established itself as a premier source for authentic Black art prints, greeting cards, and cultural products. The company offers retail and wholesale options through multiple platforms, featuring limited and open editions that celebrate religious themes, education, music, family life, and African American culture.
A milestone achievement in cultural preservation and artistic representation marks Positive Black Images continued success after more than…
BARE Laser & Skin Extends Hours and Welcomes New Clients for Professional Laser …
BARE Laser & Skin, a trusted skincare and laser treatment clinic, is pleased to announce expanded clinic hours to accommodate the growing demand for tattoo removal services in London, Ontario.
London, Ontario - Nov 17th, 2025 - BARE Laser & Skin, a trusted skincare and laser treatment clinic, is pleased to announce expanded clinic hours to accommodate the growing demand for tattoo removal services in London, Ontario [https://www.barelaserskin.ca/laser-tattoo-removal-treatments-london-ontario]. While the clinic…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
